Complex Molecular Genetic Testing Made Simple

This whitepaper explores how Asuragen, a Bio-Techne brand's AmplideX^® testing technology accelerates the journey from Clinical Trial Assay (CTA) to Companion Diagnostics (CDx) by reliably amplifying GC-rich and other repetitive DNA sequences to develop treatments for specific gene types. This accomplishment is shown through partnerships such as:

• Wave Life Sciences and Asuragen’s development of a CTA targeting the HTT gene
• Zynerba and Asuragen’s partnership in the RECONNECT Trial for Fragile X Syndrome